89.30
전일 마감가:
$90.42
열려 있는:
$89.52
하루 거래량:
687.05K
Relative Volume:
0.55
시가총액:
$10.53B
수익:
$2.77B
순이익/손실:
$286.61M
주가수익비율:
38.00
EPS:
2.35
순현금흐름:
$524.11M
1주 성능:
-0.03%
1개월 성능:
-4.99%
6개월 성능:
-23.48%
1년 성능:
-18.27%
퍼킨엘머 Stock (RVTY) Company Profile
명칭
Revvity Inc
전화
781-663-6900
주소
77 4TH AVENUE, WALTHAM
RVTY을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
RVTY
Revvity Inc
|
89.30 | 10.87B | 2.77B | 286.61M | 524.11M | 2.35 |
![]()
TMO
Thermo Fisher Scientific Inc
|
396.45 | 152.34B | 42.90B | 6.52B | 6.72B | 17.05 |
![]()
DHR
Danaher Corp
|
189.27 | 135.39B | 23.82B | 3.77B | 4.90B | 5.15 |
![]()
IDXX
Idexx Laboratories Inc
|
514.80 | 41.54B | 3.93B | 894.97M | 837.70M | 10.82 |
![]()
A
Agilent Technologies Inc
|
111.07 | 31.59B | 6.63B | 1.17B | 1.19B | 4.05 |
![]()
IQV
Iqvia Holdings Inc
|
139.06 | 24.31B | 15.50B | 1.33B | 2.16B | 7.34 |
퍼킨엘머 Stock (RVTY) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-05-01 | 업그레이드 | UBS | Neutral → Buy |
2025-01-10 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
2024-12-13 | 업그레이드 | BofA Securities | Neutral → Buy |
2024-10-15 | 업그레이드 | Barclays | Equal Weight → Overweight |
2024-08-28 | 개시 | Wells Fargo | Equal Weight |
2024-07-08 | 개시 | Leerink Partners | Outperform |
2024-06-03 | 재개 | Jefferies | Hold |
2024-01-16 | 다운그레이드 | UBS | Buy → Neutral |
2024-01-04 | 업그레이드 | Evercore ISI | In-line → Outperform |
2023-12-19 | 개시 | Wells Fargo | Equal Weight |
2023-12-13 | 개시 | Wolfe Research | Peer Perform |
2023-09-28 | 개시 | Bernstein | Outperform |
2023-07-19 | 개시 | Raymond James | Outperform |
2023-05-23 | 재개 | Goldman | Buy |
모두보기
퍼킨엘머 주식(RVTY)의 최신 뉴스
Revvity (RVTY) Introduces New Mimix Standards for Improved IVD Testing | RVTY Stock News - GuruFocus
Revvity Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows - Business Wire
Insider Sell: Michelle Mcmurry-heath Sells 600 Shares of Revvity Inc (RVTY) - GuruFocus
Does The Market Have A Low Tolerance For Revvity, Inc.'s (NYSE:RVTY) Mixed Fundamentals? - Yahoo
Shareholders in Revvity (NYSE:RVTY) are in the red if they invested three years ago - simplywall.st
Revvity Inc (RVTY) Shares Up 3.52% on May 27 - GuruFocus
RVTY Stock Falls Despite the Latest Launch of Automated Instrument - MSN
Revvity’s EUROIMMUN unveils new fully automated instrument for specialty testing - SelectScience
Enhancing Laboratory Efficiency with Revvity's IDS i20™ Platform - Lab Manager
Is Wall Street Bullish or Bearish on Revvity Stock? - inkl
Is Wall Street Bullish Or Bearish On Revvity Stock? - Barchart.com
Revvity (RVTY) Receives Affirmed Buy Rating with Promising Outlo - GuruFocus
Revvity (RVTY) Receives Affirmed Buy Rating with Promising Outlook | RVTY Stock News - GuruFocus
Sustainable chemistry in India fueling growth with digital and AI innovation: Revvity Signals - Indian Chemical News
Revvity announces launch of new fully automated instrument for specialty testing - BioSpectrum India
Revvity's EUROIMMUN Unveils New Fully Automated Instrument for S - GuruFocus
Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing | RVTY Stock News - GuruFocus
Revvity’s EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing - Business Wire
Revvity's New Automated Platform Transforms Specialty Disease Testing with 20-Analyte Capability - Stock Titan
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
Revvity Signals Software Inc. v. Cloud Software Group Inc. - Cornerstone Research
Revvity Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Global Preeclampsia Diagnostics Market to Exhibit Growth at a CAGR of ~4% by 2032 | DelveInsight - GlobeNewswire Inc.
Shareholders Will Be Pleased With The Quality of Revvity's (NYSE:RVTY) Earnings - Yahoo
Revvity at Bank of America 2025 Healthcare Conference: Navigating Tariffs and Growth - Investing.com India
Revvity To Present At Bank Of America Global Healthcare Conference 2025; Webcast At 12:20 PM ET - Nasdaq
Revvity beats quarterly estimates on steady demand for medical equipment - MSN
Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know - Yahoo Finance
RVTY Q1 Earnings Call: Resilient Performance Amid Academic and Tariff Headwinds, Software and Diagnostics Shine - Yahoo Finance
Revvity: Despite Facing Multiple Headwinds, Shares Are A Buy (NYSE:RVTY) - Seeking Alpha
High Content Screening Market Global Forecasts 2025-2030 - GlobeNewswire
High Content Screening Market Global Forecasts 2025-2030 with Danaher, Revvity, BD, Carl Zeiss, Merck, and Thermo Fisher Scientific Dominating the $2.19 Billion Market - Yahoo Finance
Revvity joins peers Thermo Fisher, Danaher in tariff warning, maintains profit outlook - MSN
Revvity Announces Financial Results for the First Quarter of 2025 - ADVFN
UBS Upgrades Revvity (BMV:RVTY) - Nasdaq
UBS Upgrades Revvity (BIT:1RVTY) - Nasdaq
UBS lifts Revvity stock rating to Buy, cuts price target to $115 - Investing.com Australia
UBS Upgrades Revvity (LSE:0KHE) - Nasdaq
UBS Upgrades Revvity (RVTY) - Nasdaq
UBS Boosts Revvity (RVTY) Rating to Buy Amid Growth Prospects | - GuruFocus
UBS lifts Revvity stock rating to Buy, cuts price target to $115 By Investing.com - Investing.com South Africa
UBS Upgrades Revvity to Buy from Neutral, Cuts Price Target to $115 From $145 - marketscreener.com
UBS Boosts Revvity (RVTY) Rating to Buy Amid Growth Prospects | RVTY Stock News - GuruFocus
Revvity to Present at Upcoming Investor Conferences | RVTY Stock News - GuruFocus
KeyBanc Adjusts Revvity's Price Target to $135 From $145 - marketscreener.com
Revvity CEO and CFO to Share Strategic Vision at BofA and Goldman Sachs Healthcare Conferences - Stock Titan
Revvity Reports Strong Q1 2025 Financial Results - TipRanks
Revvity reaffirms 2025 guidance with $4.90-$5 EPS target amid robust software growth - MSN
Stifel maintains Revvity stock Hold rating, $120 target By Investing.com - Investing.com Canada
퍼킨엘머 (RVTY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):